NL-OMON30222尚未招募不适用
The effect of a 12-week multidisciplinary treatment on the vascular function in obese children in the age of 8-17 years. - Treatment of obesity in children (8-17 years)
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational non invasive
入排标准
- 年龄范围
- 2 至 17（—）
入选标准
- •Aged 8-17 years
- •Obesity (based on the international guidelines for obesity in children, see figure 1 in appendix 1)
- •Signed informed consent
排除标准
- •Metabolic, muscular or neurologic disease
- •Specific syndroms in which obesity is an inclusion criterium (Prader-Willi syndrom)
研究者
相似试验
尚未招募
3 期
A study to evaluate efficacy and safety of combination of Glycopyrronium 25mcg/ Arformoterol 15mcg solution for inhalation in patients with chronic obstructive pulmonary disease.CTRI/2020/05/025323Glenmark Pharmaceuticals Ltd
进行中（未招募）
3 期
Efficacy and safety of low dose QMF149 (150/80 microgram)compared with MF Twisthaler® (200 microgram) in patients suffering from asthma.CTRI/2017/07/009000ovartis Healthcare Private Limited
进行中（未招募）
1 期
Efficacy and safety of low dose QMF149 (150/80 microgram) compared with MF Twisthaler® in patients with asthmaAsthmaEUCTR2016-000472-22-LTovartis Pharma Services AG802
进行中（未招募）
1 期
Efficacy and safety of low dose QMF149 (150/80 microgram) compared with MF Twisthaler® in patients with asthmaMedDRA version: 20.0 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2016-000472-22-SKovartis Pharma Services AG802
进行中（未招募）
1 期
Efficacy and safety of low dose QMF149 (150/80 microgram) compared with MF Twisthaler® in patients with asthmaAsthmaEUCTR2016-000472-22-DEovartis Pharma Services AG802